0000000000326241
AUTHOR
Eva Zusinaite
Novel activities of safe-in-human broad-spectrum antiviral agents
According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which are safe in man, and identified 59 compounds that target at least three viral diseases. We tested 55 of these compounds against eight different RNA and DNA viruses. We found novel activities for dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley feve…
Antiviral efficacy of cerium oxide nanoparticles.
The authors gratefully acknowledge the financial support by the Estonian Research Council Grants (COVSG2, PRG629, PRG1496), Estonian Centre of Excellence in Research project “Advanced materials and high-technology devices for sustainable energetics, sensorics and nanoelectronics” TK141 (2014-2020.4.01.15-0011) and University of Tartu Development Fund (PLTFYARENG53). The research was partly conducted using the NAMUR+ core facility funded by projects “Center of nanomaterials technologies and research” (2014-2020.4.01.16-0123) and TT13.